Takeda Withdraws Exkivity Amid Lung Cancer Trial Outcome Fails

Takeda withdraws Exkivity from US and EU markets after trials found the targeted therapy failed to extend survival compared to chemotherapy.

Related Keywords

United States ,China ,Switzerland ,South Korea ,Australia ,Japan ,Japanese ,Awny Farajallah ,Drug Administration ,European Union ,World Health Organization ,Global Medical Affairs Oncology At Takeda ,Rising Syphilis Rates ,Sound Alarm ,Critical Antibiotic ,Global Medical Affairs Oncology ,Dark Tea ,Diabetes Defense ,New Study Reveals Remarkable Risk ,